CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Ranked in the list of Forbes on “China’s Best Up-And-Coming Businesses”
2022-07-08

Ranked in the list of Forbes on “China’s Best Up-And-Coming Businesses”

Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Listed on the Main Board of the Stock Exchange of Hong Kong (Stock Code: 867)

Listed on the Main Board of the Stock Exchange of Hong Kong (Stock Code: 867)

Obtained the exclusive rights to promote and sell Bioflor in Mainland China

Obtained the exclusive rights to promote and sell Bioflor in Mainland China

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号